<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02530320</url>
  </required_header>
  <id_info>
    <org_study_id>GEINO 13</org_study_id>
    <nct_id>NCT02530320</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved</brief_title>
  <official_title>Phase II Pilot, Prospective, Open Label, Multicenter CT, to Evaluate the Safety and Efficacy of Palbociclib (PD0332991), a Cyclin-dependent Kinase 4 and 6 (CDK4 and CDK6) Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Español de Investigación en Neurooncología</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Grupo Español de Investigación en Neurooncología</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicenter, open-label, phase II trial aims to assess the safety and efficacy of
      palbociclib in adult patients with Oligodendroglioma or recurrent oligoastrocytoma anaplastic
      with the activity of the protein RB preserved.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS) at six months (PFS6m)</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of patients who have progressed / no progress after 6 months of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of oral administration of PD0332991 (reported adverse events, physical examinations and laboratory tests. Toxicity will be classified and tabulated by NCI-CTCAE v 4.0.)</measure>
    <time_frame>Three years</time_frame>
    <description>Type, incidence, severity, frequency, severity and relationship with IMP of reported adverse events, physical examinations and laboratory tests. Toxicity will be classified and tabulated by NCI-CTCAE v 4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-tumor response according to RANO criteria</measure>
    <time_frame>30 months</time_frame>
    <description>According to RANO criteria, assessed by the PI of each center. There will be a central review.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>30 months</time_frame>
    <description>Time from randomization to death by any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response duration</measure>
    <time_frame>30 months</time_frame>
    <description>Time from first objective response up to disease progression according RANO (in patients with objective responses).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the use of glucocorticoids</measure>
    <time_frame>30 months</time_frame>
    <description>Percentage of patients decreasing doses of corticosteroids during treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in neurological status.</measure>
    <time_frame>30 months</time_frame>
    <description>By means of minimental test, it will be determined the changes in neurological status of patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor biomarkers assessment</measure>
    <time_frame>30 months</time_frame>
    <description>It will be evaluated whether some biomarkers are related with the Progression Free Survival/Overall survival and response rates. The following biomarkers will be assessed: Deletions in CDKN2A, CDKN2B, 1p, 19q; mutations in IDH, amplifications in CDK4, CDK6, cyclin D.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Oligodendroglioma</condition>
  <condition>Oligoastrocytoma</condition>
  <arm_group>
    <arm_group_label>Palbociclib (PD0332991)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Palbociclib will be administrated orally at a dose of 125 mg/day during 21 days followed by a break of 7 days. All patients included will be treated in the same arm. Treatment will be administrated until disease progression, unacceptable adverse side effects or study end.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <description>Palbociclib will be administered orally at a dose of 125 mg/day, until disease progression, unacceptable adverse side effects or study end.</description>
    <arm_group_label>Palbociclib (PD0332991)</arm_group_label>
    <other_name>PD0332991</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ability to understand and sign the informed consent approved by the Ethic Committee.

          2. Men or women aged greater than or equal to 18.

          3. Patients with oligodendroglioma anaplastic or oligoastrocytoma anaplastic according to
             WHO classification and histologically confirmed. Note: It can be included patients
             with oligoastrocytoma or oligodendroglioma G2 only if they have suffered a recurrence
             in which the diagnosis of the resection were G3.

          4. Patients in relapse after radiotherapy and one or two lines of chemotherapy. Note:
             Both previous radiotherapy and chemotherapy could be received in adjuvant therapy or
             previous recurrences. It is also accepted to be received concurrent chemoradiotherapy.
             In the secondary oligodendrogliomas or oligoastrocytomas anaplastic, the patients
             could have received chemotherapy and radiotherapy when the tumor was G2.

          5. All patients have to present positivity in immunohistochemical study for the RB
             protein in the tumor samples sent to the central lab.

          6. The cases must have 10 slides or a tumor block available from a biopsy or surgery.

          7. All patients have to show disease progression in a cerebral nuclear magnetic
             resonance.

          8. Interval of at least one week between the previous intracranial biopsy and the
             inclusion.

          9. Interval of at least 12 weeks between radiotherapy and the inclusion, unless: a)
             Recurrent tumor confirmed histologically b) recurrency showed in the NMR out of
             radiotherapy.

         10. Patients should have been recovered from previous therapies: 28 days since the end of
             any investigational product and since the end of any cytotoxic treatment.

         11. ECOG≤2

         12. Stable or decreasing dose of corticoids during the five days prior to the inclusion

         13. patients who have been suffered from a tumor resection in the last recurrence are
             eligible if:

               -  A good surgery recover

               -  there is a measurable or evaluable disease after surgery

         14. Good bone marrow function:

               -  Neutrophils ≥ 1500/mm3 (1.5x10e9/L)

               -  Platelet ≥ 100.000/mm3 (100 x 10e9)

               -  Hemoglobin ≥ 9 g/dL

               -  Seric creatinine ≤ 1.5 x LSN of the site or estimated clearance ≥ 60 ml/min
                  calculated.

               -  Bilirubin ≤ 1.5 x LSN (if Gilbert's syndrome ≤ 3 xLSN) AST (SGOT) and/or ALT ≤ 3
                  x LSN; alkaline phosphatase ≤ 2.5 x LSN.

         15. Nor pregnant women nor breast-feeding women. Women with heterosexual activity should
             have a negative pregnant test before the inclusion in the study. Both women and men
             should use an accepted contraceptive method during the study treatment and 1 month
             after treatment completed.

        Exclusion Criteria:

          1. Presence of meningeal carcinomatosis disseminated.

          2. Concomitant treatment with other investigational products

          3. Previous treatment wih an investigational product that could be active for CDK4/6

          4. Any kind of surgery in the previous 2 weeks

          5. Presence of any clinically significant gastrointestinal abnormality that can affect
             oral administration, transit or absorption of study drug, such as the inability to
             take medication by mouth as tablets.

          6. Presence of any psychiatric or cognitive disorder that limits the understanding or the
             signature of informed consent and / or jeopardize the fulfillment of the requirements
             of this protocol.

          7. In the 7 days prior to the beginning of the treatment, to have received a treatment
             with: - Drugs inhibitor of the CYP3A4 - Drugs inductors of the CYP3A4 - Drugs that
             extends the QT interval

          8. QTc interval &gt;480 msec, familiar history or personal of QT large Syndrome, QT short
             Syndrome, Brugada syndrome, QTc extension or Torsade de Pointes history

          9. Electrolyte disorder that may affect the QTc interval

         10. Significant or uncontrolled cardiovascular disease, including:

               -  Myocardial infarction within the previous 12 months

               -  Uncontrolled angina within the previous 6 months

               -  Congestive heart failure in the previous 6 months

               -  History of clinically significant ventricular arrhythmias of any type (as
                  ventricular tachycardia, ventricular fibrillation or torsades de pointes)

               -  History of second or third grade heart block (these patients may be eligible if
                  you currently have a pacemaker)

               -  Ictus

               -  Pulmonary embolism

         11. History of any cancer, except for the following circumstances:

               -  Patients with a history of other malignancies are eligible if they have been free
                  of disease for at least the last 3 years, and at the discretion of the
                  investigator, there is low risk of disease recurrence.

               -  Patients with the following cancers are eligible even if they are diagnosed and
                  treated in the last 3 years: carcinoma in situ of the cervix and basal cell or
                  basal cell skin carcinoma. Patients are ineligible if there is evidence of any
                  neoplastic disease that required therapy other than surgery in the past 3 years.

         12. Patients positive for HIV

         13. Inflammatory bowel disease, chronic diarrhea, short gut syndrome or any upper
             gastrointestinal surgery including gastric resection.

         14. History of allergic reactions to Palbociclib

         15. Another acute or chronic serious medical condition, uncontrolled intercurrent illness
             or laboratory abnormality that may increase the risk associated with trial
             participation or investigational product administration or may interfere with the
             interpretation of test results and that,investigator's discretion, make the patient
             inappropriate for entry into this trial. Uncontrolled intercurrent illness including,
             but are not limited to, ongoing or active infection or psychiatric illness / social
             situations that limit the compliance of study requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan Manuel Sepúlveda</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. 12 de Octubre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Insular de Canarias</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <state>Las Palmas</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Vicente</last_name>
      <phone>93 434 44 12</phone>
      <email>secretaria@geino.es</email>
    </contact>
    <investigator>
      <last_name>Elena Vicente</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Mallorca</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Fuster</last_name>
      <phone>93 434 44 12</phone>
      <email>secretaria@geino.es</email>
    </contact>
    <investigator>
      <last_name>Jose Fuster</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Estela Pineda</last_name>
      <phone>93 434 44 12</phone>
      <email>secretaria@geino.es</email>
    </contact>
    <investigator>
      <last_name>Estela Pineda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO Hospitalet</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Gil Gil</last_name>
      <phone>93 434 44 12</phone>
      <email>secretaria@geino.es</email>
    </contact>
    <investigator>
      <last_name>Miguel Gil Gil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de León</name>
      <address>
        <city>León</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ángel Rodríguez</last_name>
      <phone>93 434 44 12</phone>
      <email>secretaria@geino.es</email>
    </contact>
    <investigator>
      <last_name>Ángel Rodríguez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Manuel Sepúlveda</last_name>
      <phone>93 434 44 12</phone>
      <email>secretaria@geino.es</email>
    </contact>
    <investigator>
      <last_name>Juan Manuel Sepúlveda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mª Ángeles Vaz</last_name>
      <phone>93 434 44 12</phone>
      <email>secretaria@geino.es</email>
    </contact>
    <investigator>
      <last_name>Mª Ángeles Vaz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Regional de Málaga</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gema Duran</last_name>
      <phone>93 434 44 12</phone>
      <email>secretaria@geino.es</email>
    </contact>
    <investigator>
      <last_name>Gema Duran</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Begoña Pérez</last_name>
      <phone>93 434 44 12</phone>
      <email>secretaria@geino.es</email>
    </contact>
    <investigator>
      <last_name>Begoña Pérez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2015</study_first_submitted>
  <study_first_submitted_qc>August 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2015</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Palbociclib</keyword>
  <keyword>oligodendroglioma</keyword>
  <keyword>oligoastrocytoma anaplastic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oligodendroglioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Palbociclib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

